Abiomed, Inc.

Symbol: ABMD

NASDAQ

381.02

USD

Market price today

  • 126.8485

    P/E Ratio

  • -5.7181

    PEG Ratio

  • 17.18B

    MRK Cap

  • 0.00%

    DIV Yield

Abiomed, Inc. (ABMD) Stock Price & Analysis

Shares Outstanding

45.09M

Gross Profit Margin

0.82%

Operating Profit Margin

0.36%

Net Profit Margin

0.13%

Return on Assets

0.08%

Return on Equity

0.10%

Return on Capital Employed

0.24%

Company general description and statistics

Sector: Healthcare
Industry: Medical Devices
CEO:Mr. Michael Minogue
Full-time employees:2003
City:Danvers
Address:22 CHERRY HILL DR
IPO:1987-07-29
CIK:0000815094

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

General Outlook

In simple terms, Abiomed, Inc. has 45.091 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.818% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.361%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.132%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.082% return, is a testament to Abiomed, Inc.'s adeptness in optimizing resource deployment. Abiomed, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.096%. Furthermore, the proficiency of Abiomed, Inc. in capital utilization is underscored by a remarkable 0.243% return on capital employed.

Stock Prices

Abiomed, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $377.95, while its low point bottomed out at $376.5608. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Abiomed, Inc.'s stock market.

Liquidity Ratios

Analyzing ABMD liquidity ratios reveals its financial health of the firm. The current ratio of 705.25% gauges short-term asset coverage for liabilities. The quick ratio (613.34%) assesses immediate liquidity, while the cash ratio (95.93%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio705.25%
Quick Ratio613.34%
Cash Ratio95.93%

Profitability Ratios

ABMD profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 18.47% underscores its earnings before tax deductions. The effective tax rate stands at 28.37%, revealing its tax efficiency. The net income per EBT, 71.63%, and the EBT per EBIT, 51.13%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 36.12%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin18.47%
Effective Tax Rate28.37%
Net Income per EBT71.63%
EBT per EBIT51.13%
EBIT per Revenue36.12%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 7.05, it details the span from stock purchase to revenue. The 6 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 1138.70% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding613
Days of Inventory Outstanding182
Operating Cycle214.36
Days of Payables Outstanding69
Cash Conversion Cycle146
Receivables Turnover11.39
Payables Turnover5.32
Inventory Turnover2.00
Fixed Asset Turnover4.87
Asset Turnover0.62

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 6.28, and free cash flow per share, 5.49, depict cash generation on a per-share basis. The cash per share value, 16.69, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.28, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share6.28
Free Cash Flow per Share5.49
Cash per Share16.69
Operating Cash Flow Sales Ratio0.28
Free Cash Flow to Operating Cash Flow Ratio0.87
Capital Expenditure Coverage Ratio7.98
Dividend Paid and Capex Coverage Ratio7.98

Debt and Leverage Ratios

An interest coverage of 7.48 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage7.48
Company Equity Multiplier1.11

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 22.70, provides a glimpse into top-line earnings distributed across each share. Net income per share, 3.00, reflects the portion of profit attributed to each share. The book value per share, 33.08, represents the net asset value distributed per share, while the tangible book value per share, 30.39, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share22.70
Net Income Per Share3.00
Book Value Per Share33.08
Tangible Book Value Per Share30.39
Shareholders Equity Per Share33.08
Interest Debt Per Share1.10
Capex Per Share-0.79

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 14,920,383,800, captures the company's total value, considering both debt and equity. Income quality, 2.09, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 7.32%, indicates the value of non-physical assets, and capex to operating cash flow, -12.53%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value14,920,383,800
Income Quality2.09
Research and Development to Revenue15.84%
Intangibles to Total Assets7.32%
Capex to Operating Cash Flow-12.53%
Capex to Revenue-3.47%
Capex to Depreciation-127.32%
Stock-Based Compensation to Revenue5.11%
Graham Number47.28
Return on Tangible Assets8.80%
Graham Net Net15.48
Working Capital838,016,000
Tangible Asset Value1,380,904,000
Net Current Asset Value806,406,000
Average Receivables93,893,500
Average Payables35,094,000
Average Inventory87,520,000
Days Sales Outstanding32
Days Payables Outstanding69
Days of Inventory On Hand182
ROIC17.76%
ROE0.09%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 11.52, and the price to book ratio, 11.52, reflect the market's valuation relative to the company's book value. The price to sales ratio, 16.65, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 68.83, and price to operating cash flows, 60.67, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio11.52
Price to Book Ratio11.52
Price to Sales Ratio16.65
Price Cash Flow Ratio60.67
Price Earnings to Growth Ratio-5.72
Enterprise Value Multiple43.20
Price Fair Value11.52
Price to Operating Cash Flow Ratio60.67
Price to Free Cash Flows Ratio68.83
Price to Tangible Book Ratio10.01
Enterprise Value to Sales14.46
Enterprise Value Over EBITDA37.23
EV to Operating Cash Flow52.28
Earnings Yield0.91%
Free Cash Flow Yield1.66%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Abiomed, Inc. (ABMD) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 126.848 in 2024.

What is the ticker symbol of Abiomed, Inc. stock?

The ticker symbol of Abiomed, Inc. stock is ABMD.

What is company IPO date?

IPO date of Abiomed, Inc. is 1987-07-29.

What is company current share price?

Current share price is 381.020 USD.

What is stock market cap today?

The market cap of stock today is 17180649472.000.

What is PEG ratio in 2024?

The current -5.718 is -5.718 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2003.